|
|
|
01.07.25 - 13:09
|
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025 (Business Wire)
|
|
|
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.
The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call.
To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 859170.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most c...
|
|
|
24.06.25 - 13:06
|
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors (Business Wire)
|
|
|
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck.
Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue and pipeline investment.
“We are thrilled to welcome Marjorie to the NeoGenomics Board,” said Lynn Tetrault, Chair of the Board of NeoGenomics. “Dr. Green's deep expertise in clinical oncology and pipeline development, combined with her experience in business development, will be...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.04.25 - 13:33
|
NeoGenomics Reports First Quarter 2025 Results (Business Wire)
|
|
|
Consolidated Revenue Increased 8% to $168 million
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025.
First Quarter 2025 Highlights As Compared To First Quarter 2024
Consolidated revenue increased 8% to $168 million
Net loss decreased 4% to $26 million
Adjusted EBITDA increased 102% to positive $7 million
“Our business is off to a solid start in 2025 with our team delivering a record number of results to patients in the first quarter and improving our adjusted EBITDA by over 100% from prior year,” said Tony Zook, CEO of NeoGenomics. “We expect to continue to accelerate growth as we expand our portfolio with upcoming product launches, win on customer experience and capitalize on our world-class sales force, supporting our mission to improve patient care.”
First-Quarter Results
Consolidated revenue for t...
|
|
|
|
|
22.04.25 - 13:06
|
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting (Business Wire)
|
|
|
Additional Presentations Demonstrate Ongoing Commitment to Research & Innovation in Precision Oncology
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, today announced the analytical validation of its PanTracer LBx™ assay, a next-generation sequencing (NGS) liquid biopsy panel designed for comprehensive pan-solid tumor profiling. The validation study, along with five additional abstracts, will be presented at the American Association for Cancer Research® (AACR) Annual Meeting 2025 in Chicago, April 25–30.
PanTracer LBx is a blood-based test that analyzes circulating tumor DNA to identify key genomic alterations in patients with advanced-stage solid tumors. It is designed to support treatment decisions when tumor tissue is unavailable or insufficient—a common challenge in oncology care. In the validation study, PanTracer LBx demonstrated high performance in identifying key biomarkers—includi...
|
|
|
08.04.25 - 13:09
|
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025 (Business Wire)
|
|
|
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.
The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call.
To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 603651.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most c...
|
|
|
07.04.25 - 13:06
|
NeoGenomics Completes Acquisition of Pathline (Business Wire)
|
|
|
Patients and physicians will benefit from access to NeoGenomics' broad test menu and high-quality laboratory services in the Tri-state area
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.
With the acquisition, NeoGenomics strengthens its commercial presence in the Northeast U.S. and broadens access to its comprehensive oncology test menu, expands its service capabilities, and accelerates growth in molecular and hematology-oncology testing.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hosp...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
